Invisible and intangible illness:a qualitative interview study of patients' experiences and understandings of conservatively managed end-stage kidney disease by Bristowe, Katherine et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.21037/apm.2018.12.06
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Bristowe, K., Selman, L. E., Higginson, I. J., & Murtagh, F. E. M. (2019). Invisible and intangible illness: a
qualitative interview study of patients' experiences and understandings of conservatively managed end-stage
kidney disease. Annals of Palliative Medicine. https://doi.org/10.21037/apm.2018.12.06
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 05. Apr. 2019
© Annals of Palliative Medicine. All rights reserved.   Ann Palliat Med 2018apm.amegroups.com
Original Article
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Background: Increasing numbers of older adults are living with kidney disease. For those with 
comorbidities, conservative management of end-stage kidney disease is a viable option: dialysis may afford 
limited or no survival benefit, and perceived burdens may outweigh benefits. Conservative management 
focuses on: maintaining remaining kidney function; symptom management; and quality of life. Common 
symptoms in conservatively managed kidney disease include: fatigue; anorexia; nausea and vomiting; pain 
and pruritis. Chronic disease is associated with biographical disruption and a loss of sense of self. Coping 
strategies are shaped by illness perceptions, but little is known of illness perceptions of people living 
with conservatively managed kidney disease. This study aimed to explore the experience, impact and 
understanding of conservatively managed end-stage kidney disease among older adults. 
Methods: Secondary analysis of qualitative interviews analysed using thematic analysis. Twenty people with 
conservatively managed end-stage kidney disease were recruited from 3 UK renal units: median age was  
82 (range, 69–95); 9 women, 11 men.
Results: Participants described the invisibility and intangibility of kidney disease, and challenges in 
attributing symptoms to the disease. They described a spectre-like presence, sapping their energy and 
holding them down. For some, it was hard to differentiate symptoms of the illness from characteristics of 
aging, resulting in challenges in illness attribution, and disconnectedness from the illness. 
Conclusions: Participants described challenges in attributing their symptoms to kidney disease which 
negatively impacted upon their wellbeing, and ability to accept an adjusted sense of self. Understanding these 
challenges is critical in the management conditions such as end-stage kidney disease where prognosis may 
be poor, and where an increase in symptom distress may suggest a marked deterioration in their condition, 
or a change in phase of illness. Clinical services need to recognize the illness experience (alongside more 
symptom led approaches), including the invisibility, intangibility, and disconnectedness, and address this 
through specific interventions focused on improving clinical assessment, communication and education, 
alongside peer and professional support.
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Introduction
Over the last decade the number of people dying from 
chronic kidney disease has increased by almost one third 
(25.5–31.4%); this equates to approximately 1.2 million 
people dying each year from kidney disease globally (1). 
There has also been a marked shift towards deaths at older 
ages since the 1990s (1), and the end-stage kidney disease 
population is increasingly elderly and co-morbid (2). 
For older adults facing a decision regarding renal 
replacement therapy, although survival in receipt of dialysis 
will most likely be longer, the burden of accessing dialysis 
may outweigh the survival benefit for some patients (3). 
Dialysis impacts heavily on quality of life requiring frequent 
hospital attendance (86% receive haemodialysis in hospital, 
14% at home), usually 3 times per week (4). Conservative 
kidney management is considered a viable and beneficial 
option for older adults with comorbidities, particularly 
ischemic heart disease, for whom survival benefit of dialysis 
may be negligible (5-7). Patients receiving conservative 
management spend less time having treatment, and are less 
likely to require hospital admissions or die in hospital (8). 
However, access to and awareness of conservative 
management for older adults varies nationally, and depends 
partly on the degree to which conservative management 
is an established pathway within each unit (9,10). Such 
pathways include careful monitoring, interventions to 
delay progression of kidney disease, and management of 
uraemia and burdensome symptoms including, but not 
limited to: fatigue; anorexia; nausea and vomiting; pain and 
pruritis (11,12). People with conservatively managed end-
stage kidney disease have considerable symptom control 
needs, similar to advanced cancer populations (12). 
Longitudinal research has shown a sharp increase in 
symptom distress and health related concerns for patients 
with conservatively managed kidney disease in the last 
2 months of life (13).
The impact of chronic illness or long-term conditions 
upon the individual and those close to them has long been 
recognised. The ‘biographical disruption’ experienced 
often requires a fundamental rethinking of one’s identity, 
including plans and expectations (14). Chronic illness is also 
associated with loss of self, or former self, and suffering, 
often resulting in withdrawal and isolation (15). The coping 
strategies that individuals develop, however, are influenced 
by their perceptions and interpretations of their illness (16). 
Research has highlighted the physical, social and 
psychological impact of kidney disease upon individuals (17-19), 
but has focused primarily on those in receipt of dialysis 
or transplant. The limited research into the experiences 
of those in receipt of conservative kidney management 
has focused on reasons for choosing that pathway (20-24), 
including communication and information provision, 
rather than the impact and understanding of their illness 
thereafter. This study therefore aimed to explore the 
experiences of older adults living with kidney disease that 
was being managed conservatively to examine: the impact 
of their illness, including the impact over time; and their 
understanding of the illness to inform clinical practice and 
policy. 
Methods
Design
Secondary analysis of qualitative interview data. According 
to the typology of secondary analyses, this study represents 
a ‘supplementary analysis’ whereby the analysis focuses 
on emergent themes which were not addressed, or only 
partially addressed, by the primary analysis (25).
Setting
Participants were recruited from three renal units across South 
London and the South East of England, as part of a larger 
longitudinal study mixed methods (13). Participation in the 
larger study included consent for access to medical records, 
sharing of demographic information, a longitudinal quantitative 
survey [data from which are reported elsewhere (13)], 
and a single in depth qualitative interview undertaken 
in 2007 (secondary analysis of these interview data are 
reported in the current paper). 
Governance
Ethical approval for the study was received by King’s 
College Hospital Research Ethics Committee (COREC: 
04/03/092). Local R&D and ethical approvals were 
acquired at each site. As the supplementary analysis of the 
data undertaken fell within the broad aims and objectives of 
the original study, no further approvals were required.
Sampling
Participants were purposively sampled for diversity by: age; 
co-morbidity (assessed using the Charlson Comorbidity 
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Index (26) modified for renal patients which excludes renal 
diagnosis and age from the scoring (27) and functional status 
[assessed using the Karnofsky Performance Status (28)].
Inclusion criteria
Adults (>18 years) under the care of nephrologists with stage 
5 chronic kidney disease (CKD) with estimated glomerular 
filtration rate (eGFR) ≤15 mL/minute and a confirmed 
(by nephrologist) decision for conservative management 
(management without dialysis or renal replacement 
therapy). 
Exclusion criteria 
Lacking capacity to give consent to participate in the study. 
Recruitment
Potentially eligible patients were identified by their 
clinicians, after assessment of their capacity at a clinic 
appointment, and given verbal and written information 
about the study. Clinicians sought permission for the 
researcher (FE Murtagh) to make contact, and the preferred 
means of that contact. At least 24 hours after this first 
approach, the researcher contacted those who had expressed 
an interest in participation. Only one of the participants 
who was approached declined interview, as they felt too 
unwell. For all others a further appointment was then 
made, at the patient’s preferred location, at which written 
informed consent was taken to participate in the study, and 
the interview conducted. Recruitment continued until data 
saturation was achieved and no new themes, related to the 
aims and objectives of the original study, were emerging 
from subsequent interviews.
Interviews
Qualitative interviews were chosen to allow in-depth 
exploration of the illness experience for older adults living 
with kidney disease. A topic guide was developed, and 
piloted with three participants before being finalised (pilot 
interview data not included). In-depth interviews were 
conducted in the participant’s preferred location (all in their 
usual place of residence), to explore their experiences of 
the illness, the impact of their illness and symptoms, and 
their involvement in decision-making. For 13 interviews, 
only the patient was present in the room for the interview; 
the remaining seven participants chose for their spouse 
or a relative to remain in the room. All interviews were 
conducted by FE Murtagh, a palliative care clinician. She 
was not known to the participants, was not involved in their 
care, and was introduced as a researcher. Interviews were 
audio recorded, transcribed verbatim and anonymised. 
Field notes were also taken at the time of the interview 
and immediately after, to capture contextual factors. No 
repeat interviews were undertaken, and transcripts were not 
returned to participants for comments. 
Analysis
Interviews were transcribed verbatim, and transcripts 
were anonymised with allocation of culturally appropriate 
pseudonyms. The study was positioned within a subtle 
realist paradigm which assumes that there is an objective 
reality, but that it can only be understood through an 
individual’s perspective of it (29). Interviews were analysed 
inductively using thematic analysis (30,31), which involved 
six steps: familiarisation; coding; searching; reviewing; and 
defining themes; and reporting. This method was chosen 
as it offers the researcher an accessible and theoretically 
flexible approach to analysing qualitative data, shaped 
to the research question and epistemology (32). The 
researcher (FE Murtagh) had not previously undertaken 
in-depth interviews, although had completed an intensive 
training course at the National Centre for Social Research 
to develop these skills. Early transcripts were critically 
reviewed by an independent experienced qualitative 
interviewer, to provide feedback and to refine techniques. 
Analysis was further discussed and refined by FE Murtagh, 
K Bristowe and LE Selman. Analysis was supported by QSR 
NVivo qualitative data analysis software. 
Results
Participants
Twenty older people (>65) living with kidney disease were 
interviewed. The participants: had a median age of 82 years 
(range, 69–95); 11 were men and 9 women; 18 were of white 
ethnicity, one black Caribbean, and one other ethnicity 
(ethnicity was categorised according to those used in UK 
Renal Registry report); 8 were married, 9 were widowed, 
and 3 were single; 10 were living alone, 7 with their spouse, 
2 with family (both with daughters), and 1 in a nursing 
home (see Table 1). Median Karnofsky Performance Status 
score was 60% (range, 40–80%) (28), and median modified 
Charlson Comorbidity Index score (which excludes renal 
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diagnosis and age from the scoring) was 4 (range, 4–8) (27). 
The duration of the interviews ranged from 38 to 74 minutes.
Findings
Participants described the challenges of living with 
kidney disease, particularly in terms of its hidden nature. 
They described it as invisible and intangible, struggling 
to attribute symptoms to the illness, whilst also feeling 
disconnected from it. This combination of invisibility and 
intangibility, alongside the unpredictable nature of the 
illness, impacted heavily on individuals’ quality of life. 
Invisibility
In expressing their experience of the illness, kidney disease 
was described by participants as a ‘hidden’ or ‘invisible’ 
illness. Participants made reference, with varying degrees 
of detail, to the perception that they were in the grip 
of something unseen. Jack, for instance, gave a graphic 
description of his kidney disease as an invisible illness.
“Like there’s something bubbling along in your blood that you 
don’t know quite what it will do, and you can’t see it.” (Jack, 
84 years old).
Several participants contrasted kidney disease with other 
illnesses that they had experienced, pointing out the lack 
of form or identity for themselves or others to grasp. Jean 
described it as something hidden from her, with ‘nothing 
to show for it’, contrasting it with her (severe) arthritis that 
was visible in her hands and knees.
“There isn’t anything like I could say ‘this is the kidney 
problem doing this’—it is all a bit more silent, going along there 
but without me really knowing, brewing away but nothing to see 
really…I mean, they tell you the kidney isn’t good, but well…how 
do I know? There’s nothing to show for it, is there?...I’m not to 
know, am I? It’s kind of hidden, I don’t know it’s there.” (Jean, 
81 years old).
The lack of form and invisibility of kidney disease was 
further underpinned by descriptions of the illness almost as 
a ‘spectre’ or ‘being’, which would ‘creep up on you’, giving 
it agency and control over individuals’ actions. 
“Yes, and you don’t notice it, for a while you don’t really notice 
that you’re giving things up, it kind of creeps up on you, and then 
suddenly you do things like, a major one was why the hell get 
dressed when it takes me an hour to get dressed, why not just stay 
in my dressing gown.” (Charles, 77 years old).
The unpredictability and lack of control associated with 
the illness was particularly challenging for George, who 
Table 1 Participant characteristics
Participants n=20
Gender
Female 11
Male 9
Age
<75 2
75–79 5
80–84 8
≥85 5
Marital status
Married 8
Widowed 9
Single 3
Renal diagnosis
Diabetes mellitus 5
Glomerulo-nephritis 3
Renal vascular disease 2
Unknown 9
Other 1
Karnofsky Performance Status score
40% 3
50% 3
60% 4
70% 7
80% 3
Median 60%
Range 40–80%
Modified Charlson Comorbidity Index score*
2 2
3 5
4 5
5 4
6 3
8 1
Median 4
Range 2–8
*, Charlson Comorbidity Index modified for renal patients which 
excludes renal diagnosis and age from the scoring (27).
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described being ‘in the hands of a mystery’.
“It’s like it’s some vis…invisible thing going on, and we 
don’t know. I mean they know the kidneys is bad, don’t they, but 
why does it go up and down and why does it, it causes all these 
problems? We’re in the hands of a mystery, I think.” (George, 
95 years old).
Intangibility
A further extension of the invisibility of the kidney disease 
involved challenges in attributing symptoms to the illness. 
Participants described not knowing whether it was the 
illness causing symptoms or problems, whether they were 
age-related, or caused by other co-morbid conditions. This 
contributed to the sense of intangibility of the illness, as 
described by Grace.
“But I don’t know if that be kidney or not. My heart’s bad 
and my breathing sometimes, and my legs play me bad at night. 
It could be all that, or something’ else, I don’t know (laughs).” 
(Grace, 73 years old).
Other participants were also uncertain, not in describing 
the symptoms, but in knowing what had caused them. 
Some, such as Harold, who was 82 years old, included their 
age as a possible reason for symptoms or problems.
“Another thing is I find I get very tired these days, I don’t 
know whether it’s that (meaning his kidney disease) or old age, 
I mean, you know, I’ve never been this age before.” (Harold, 
82 years old).
This  uncertainty in attr ibution contributed to 
participants’ sense of a loss of control. Not only could they 
do little about the effects of the illness, but neither could 
participants explain what was causing them. This in turn 
influenced their feelings towards their illness and their 
perception of other people’s attitudes towards them. 
“With my kidneys…it’s, well…hard to say, I just feel tired and 
no energy, and generally not myself, all vague and sounds like I’m 
just…complaining or something. Making a fuss about nothing 
(laughs)”. (Donald, 89 years old).
The loss of control experienced by individuals was 
exacerbated by the unpredictable nature of kidney disease, 
which severely impacted on their ability to complete or plan 
day-to-day activities, negatively affecting their quality of 
life. Specifically, some individuals described not being able 
to predict a deterioration from one day to the next.
“The worst of it is, I never quite know how I’m going to be. 
Sometimes I can get up and I’ll be fine, it will be a good day, and 
that will carry on for a bit, and then out the blue, it all goes, like 
I’ve run out of petrol or something, and there’s nothing in the 
tank. I can feel unwell for days then, but I never really know why 
it’s like that, this way, that way, can’t tell how I’ll be.” (Florence, 
82 years old).
The physical impact of kidney disease was also described 
as vague or intangible, beyond tiredness or fatigue, almost 
as a weight, holding you down, suspending your ability to 
carry out activities. 
“It’s hard to describe….It’s rather like someone put lead 
weights on your shoulders or something, you just can’t get up and 
get going. It runs through everything, all the time. Sometimes 
it’s not so bad for a few weeks, and I think maybe I can do a few 
things, then suddenly it’s back again, and I can’t get going…” 
(Betty, 79 years old).
This sense of being held down was also described as a 
loss of ‘get up and go’, lack of ‘impetus’, feeling they had no 
‘fuel in the tank’, or ‘lifelessness’. This effect was pervasive, 
impacting on all aspects of daily living, and the burden was 
exacerbated due to the unpredictability of the illness.
“The energy levels too, it was just steadily getting worse. 
Harder to do things, like I said, it’s hard to explain, but it 
was very difficult to say ‘I’m going to do this,’ and then do it. 
Normally you don’t think of it, you just get on and do, don’t 
you, but here I was, spending 20, 30 minutes saying ‘I’m going 
to do’ and then still not doing, oh, even the simplest of things.” 
(Franklyn, 86 years old).
For many the stark contrast between their life now and 
prior to their illness was overwhelming, particularly due 
to the often sudden deterioration affecting all aspects of 
their life.
“It has affected me terrible. Yes, you know. Nothing is the 
same…I don’t have the strength or the energy any more, it makes 
me feel useless, I couldn’t do what I wanted to do any more, but, 
there you are, you know what I mean, it’s so bad, I mean now I 
can’t even write, I can’t write properly….I don’t know. It just 
seems to have struck me right down, it just came down like a ton 
of bricks, you know, it came right down on top of me.” (Dorothy, 
84 years old).
Disconnectedness
The invisible nature of the disease was also associated with 
a feeling of disconnectedness from it. Donald felt it was 
professionals who were telling him of his illness, but that 
this did not correspond to the evidence from his own senses; 
as he said, ‘can’t see it, don’t feel it’.
“I dunno, dunno as it has affected me. Can’t pin anything 
down, that’s what I said to Dr. (GP’s name). Can’t see it, don’t 
feel it. Wouldn’t know about it, but for them….It’s like someone 
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tells you…your kidneys are bad…but it’s nothing to do with you, 
you have to believe them.”
And he later went on to say: 
“If it’s my heart, then I might get pain, alright I don’t know 
if it’s indigestion or what, but I get a pain. With my kidneys…
it’s, well…hard to say, I just feel tired and no energy.” (Donald, 
89 years old).
Others felt unable to pinpoint the illness as a specific 
cause, and relied on professionals to tell them what was 
happening.
“But it’s hard, if you have a pain in your back, you know it’s 
your back, if you have a muscle go in your hand, it’s in your hand. 
But you don’t know what your kidneys are doing do you, so it’s 
hard to say anything much about them, you have to go on what 
they (clinicians) say to you, with them bloods and that what they 
take.” (Alice, 82 years old).
The invisibility and intangibility of the illness fueled 
the sense of disconnectedness from it. Collectively, these 
resulted in challenges in attributing symptoms to the kidney 
disease, reduced ability to plan and engage in activities, and 
poor quality of life. 
Discussion
This is one of relatively few studies to examine the experience 
of older adults living with end-stage kidney disease in 
receipt of conservative kidney management. Participants 
described the invisibility and intangibility of kidney disease, 
the challenges of attributing symptoms to the disease, and 
the unpredictable, and often sudden, nature of deterioration 
over time. They described a spectre-like presence or force, 
sapping their energy and holding them down. For some, it 
was hard to differentiate the symptoms of the illness from 
characteristics of ageing, resulting in challenges in illness 
attribution, and a sense of disconnectedness from the illness. 
Challenges in illness attribution have been recognised 
in other invisible illnesses including osteoporosis, where 
lack of symptoms created doubt and ambivalence regarding 
diagnosis (33), SLE (systemic lupus erythematosus) 
where invisibility had detrimental effects on adjustment 
(34) ,  and COPD (chronic obstructive pulmonary 
disease) where invisible signs of deterioration were not 
recognised by professionals (35). Indeed, as in the present 
study, where the condition is perceived as abstract, this 
impacts on the ability to make sense of and cope with 
illness (16). The invisibility and intangibility of kidney 
disease resulted in participants’ lack of understanding 
of their illness, uncertainty, and a resultant inability to 
attribute symptoms and concerns to the illness. This was 
associated with a loss of self (15) to a liminal state between 
illness and wellness (36,37), and a lack of access to the 
sick role (38), and the associated rights and obligations. 
The challenges of managing uncertainty in the context of 
advanced illness have also been recognised in cancer, heart 
failure, COPD and liver disease. Better understanding of 
the patient’s goals and temporal focus (present or future), 
alongside exploration of their information needs and 
engagement with illness is critical to enable open and 
honest discussions about future care and preferences (39). 
Indeed, in the present study although participants spoke 
about deterioration more broadly and referred implicitly to 
their deterioration and death, very few spoke overtly about 
end of life care or used terms of this type.
Previous studies have recognised the variation in 
understanding of the nature and purpose of conservative 
kidney management across the UK (9,10). This disparity 
often appears to stem from inadequate communication 
about: the distinction between conservative care and more 
interventional approaches; prognosis; and the palliative 
nature of conservative care (40). Indeed nephrologists 
describe a reluctance to open discussions about prognosis 
with their patients until a deterioration is evident, due to 
long established relationships with patients and to avoid 
causing distress (41,42). The present study supports a 
need for improved communication, education and support 
regarding conservative care pathways, at the point of critical 
decisions, including: expectations with regard to symptoms 
and impact of the disease upon the lifeworld, alongside 
consideration of the burden of dialysis. Research has 
highlighted that nephrologists underestimate the presence 
and severity of symptoms for haemodialysis patients (43). It 
is critical that regular assessment of conservatively managed 
patients includes psychological, social and spiritual domains, 
alongside physical concerns, to ensure that: symptoms 
and concerns are recognised and addressed. Moreover, it 
is essential that adjunct services to provide psychological, 
social and spiritual support are equally available to 
conservatively managed patients who may rarely attend 
the hospital, as they are for those attending regularly for 
dialysis. 
Strengths and limitations
This study has both strengths and limitations. The study 
sample represents a maximum variation sample, with 
regard to age, living situation, levels of co-morbidity and 
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functional status, which adequately reflects the variability 
within this population. As this is a qualitative study, it does 
not seek for findings to be generalisable, however findings 
would be transferable to other sites with aging end-stage 
kidney disease populations. Most participants in the study 
were of white ethnicity, reflecting the UK population 
and the catchment population for the three renal units. 
Further interviews with individuals from Black, Asian and 
minority ethnic communities would have increased the 
transferability of these findings. Seven individuals chose to 
undertake interviews with a family member present in the 
room. Whilst they did not participate in the interviews, it 
is possible that their presence may have influenced some 
responses to questions. However, we chose to undertake 
interviews in line with the preferences of each individual, 
some of whom preferred to have someone else present for 
support. The data for this study were originally collected 
in 2007, since which time conservative management has 
become a more accepted component of renal care. However 
there is recent evidence of significant variability in service 
delivery across renal units (44), and there continues to be 
a lack of research exploring the lived experiences of people 
living with conservatively managed kidney disease. Our 
findings are therefore still novel and highly relevant. As a 
secondary (supplementary) analysis of an existing dataset, 
it was not possible to undertake an iterative process of 
recruitment and analysis, and therefore data saturation was 
more challenging to assess. The original study addressed 
wider aims related to the experience of conservative 
kidney care, with themes across broader domains. Primary 
research focusing specifically on the invisibility and 
intangibility of kidney disease may extend our findings. 
Given the social and psychological impact of end-stage 
kidney disease beyond the individual living with the disease, 
further interviews with informal caregivers, and healthcare 
professionals delivering conservative kidney care, would 
also be beneficial, to further examine the invisibility and 
intangibility of this condition. In addition, longitudinal 
qualitative work with diverse patient groups would enable 
further exploration of how perspectives and understandings 
of conservatively managed kidney disease evolve over time, 
to inform intervention development.
Conclusions
This original paper describes, for the first time, the 
profound invisibility and intangibility of the illness 
perceived by those people with end-stage kidney disease 
managed conservatively, without dialysis. Challenges in 
differentiating the burdensome symptoms of end-stage 
kidney disease from normal aging are shared with other 
illnesses, but the profound intangibility causes major 
challenges to individuals’ sense of self and obstructs 
development of realistic hopes and aspirations (45). A 
sharp increase in symptom distress and health concerns 
for those with conservatively managed kidney disease 
may suggest a marked deterioration or change in phase 
of illness, demonstrating the importance of recognition 
and management of symptoms (13). However, differences 
between the patient’s interpretation of this intangible 
illness and its effects on their life, and the professional’s 
biomedical symptom focused approach, may preclude 
meaningful discussions about problems, concerns and future 
care (46). Clinical services need to recognise the invisibility, 
intangibility, and related sense of disconnectedness, 
and address this through specific interventions focused 
on improving clinical assessment and communication, 
education, peer support, and professional support. 
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